Form 4: Artiva Biotherapeutics SVP Tax-Related Share Withholding
Insider Transaction Report
Artiva Biotherapeutics' SVP of Research and Development, Heather Raymon, had shares withheld to cover tax obligations from restricted stock unit vesting.
Summary
- Heather Raymon, SVP of Research and Development at Artiva Biotherapeutics, Inc. (ARTV), reported changes in beneficial ownership.
- On May 15, 2025, 745 shares of common stock were disposed of at a price of $2.13 per share.
- On August 15, 2025, an additional 1,639 shares of common stock were disposed of at a price of $2.75 per share.
- These dispositions represent shares withheld by Artiva Biotherapeutics to satisfy income tax obligations related to the vesting of restricted stock unit awards.
- Following these transactions, Heather Raymon beneficially owns 40,966 shares of common stock directly.
Sentiment
Score: 5
Explanation: Neutral. The filing reports routine tax-related share withholdings, which are standard compensation events and do not indicate significant positive or negative operational or financial news for the company.
Positives
- The transactions are routine tax-related withholdings, indicating the vesting of restricted stock units, which can be a positive for employee retention and compensation.
Negatives
- The transactions resulted in a reduction of Heather Raymon's direct beneficial ownership by a total of 2,384 shares (745 + 1,639).
Future Outlook
NA
Industry Context
This filing is a routine insider transaction report for a biotechnology company. Such tax-related share withholdings are common across all industries when restricted stock units vest, and do not typically reflect specific industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Minor dilution from shares withheld, but generally a non-event as it's a standard compensation mechanism.
- Employees: Indicates vesting of RSU awards, which is positive for employee compensation and retention.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Transaction date for disposition of 745 common shares for tax obligations. |
| 08/15/2025 | Transaction date for disposition of 1,639 common shares for tax obligations. |
| 08/18/2025 | Signature date of the reporting person's attorney-in-fact. |
Recommendation
holdThe filing details routine tax-related share withholdings by an executive, which is a common and expected event for executive compensation. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing does not present a catalyst for significant price movement.
Keywords
Artiva Biotherapeutics, ARTV, SEC Form 4, Insider Trading, Share Withholding, Restricted Stock Units, Executive Compensation, Heather Raymon, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.